Orion Group Financial Statement Release January–December 2023
February 13, 2024 05:00 ET
|
Orion Oyj
ORION CORPORATION FINANCIAL STATEMENT RELEASE 1-12/2023 13 FEBRUARY 2024 at 12:00 EET Orion Group Financial Statement Release January–December 2023 Net sales totalled EUR 1,189.7...
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
February 05, 2024 09:00 ET
|
Yiviva
NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed...
Non-metastatic Prostate Cancer (nmPC) Market, Epidemiology, and Forecast - Strategic Insight until 2032
January 24, 2024 10:39 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's...
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
January 08, 2024 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032
January 04, 2024 18:33 ET
|
Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This...
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
December 06, 2023 08:30 ET
|
Celcuity Inc.
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from...
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
December 01, 2023 11:02 ET
|
Celcuity Inc.
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an...
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023 08:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 13, 2023 07:05 ET
|
Celcuity Inc.
Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a...
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
November 06, 2023 07:30 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...